{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:33:26Z","timestamp":1788449606951,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical evidence raises the issues regarding the high risk of adverse events and serious bleeding in East Asian patients receiving standard-dose ticagrelor treatment. We sought to evaluate the association between adverse events and their associations with premature discontinuation of dual antiplatelet therapy (DAPT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled East Asian patients presented with acute coronary syndrome who took DAPT with 90-mg ticagrelor (<jats:italic>n<\/jats:italic> = 270) or 75-mg clopidogrel (<jats:italic>n<\/jats:italic> = 674). During 1-month treatment, antiplatelet effect was evaluated with the VerifyNow P2Y12 assay, and the occurrence of Bleeding Academic Research Consortium (BARC) bleeding and modified Medical Research Council (mMRC) dyspnea was assessed with the dedicated questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During 1-month follow-up, patients on ticagrelor showed the higher risks of bleeding (any BARC type: 45.6% vs. 23.6%; odds ratio [OR], 2.71 and BARC 1 or 2 type: 45.2% vs. 22.1%; OR, 2.90, respectively) and dyspnea (26.3% vs. 13.6%; OR, 2.25) compared with those on clopidogrel. In a receiver-operating characteristics curve analysis to predict bleeding risk, ticagrelor showed a lower cutoff of low platelet reactivity (LPR) (P2Y12 reaction unit [PRU] \u2264 20) than clopidogrel (PRU \u2264 110). Early occurrence of bleeding episode was significantly associated with LPR phenotype (OR, 2.68), not type of P2Y<jats:sub>12<\/jats:sub> inhibitor. In multivariate analysis, type of P2Y<jats:sub>12<\/jats:sub> inhibitor (ticagrelor vs. clopidogrel: OR, 2.19) and bleeding episode (OR, 2.94) were independent predictors for dyspnea occurrence. During 1-year follow-up, DAPT with ticagrelor showed a higher risk of premature discontinuation compared to DAPT with clopidogrel (27.8% vs. 4.7%; adjusted HR, 8.84), which risk appeared frequent during the first month (14.4%) during DAPT with ticagrelor. Early occurrence of bleeding and dyspnea synergistically increased a risk of DAPT non-adherence, irrespective of type of P2Y<jats:sub>12<\/jats:sub> inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This analysis is the first evidence to show the different cutoff of low platelet reactivity during the reversible (ticagrelor) versus irreversible P2Y<jats:sub>12<\/jats:sub> inhibitor (clopidogrel). Early occurrence of bleeding and dyspnea is very common during standard-dose ticagrelor treatment in East Asian patients, which show a close association with premature DAPT discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>[<jats:ext-link>https:\/\/www.clinicaltrials.gov<\/jats:ext-link>], identifier[NCT046 50529].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1053867","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:37:20Z","timestamp":1670823440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Min Gyu","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyehwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeng Rang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jae","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwhi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","article-title":"Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 Trial.","volume":"1","author":"Bonaca","year":"2016","journal-title":"JAMA Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial.","volume":"140","author":"Park","year":"2019","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","article-title":"Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"324","author":"You","year":"2020","journal-title":"JAMA."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019467","article-title":"Risk of major bleeding with potent antiplatelet agents after an acute coronary event: a comparison of ticagrelor and clopidogrel in 5116 consecutive patients in clinical practice.","volume":"10","author":"Mullen","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial.","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial.","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies.","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease.","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week.","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s11239-020-02103-w","article-title":"The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease.","volume":"50","author":"Bae","year":"2020","journal-title":"J Thromb Thrombolysis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/HCQ.0000000000000059","article-title":"2020 AHA\/ACC key data elements and definitions for coronary revascularization: a report of the American College of Cardiology\/American Heart Association Task Force on clinical data standards (writing committee to develop clinical data standards for coronary revascularization).","volume":"13","author":"Dehmer","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial.","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea.","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2012.03.022","article-title":"Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.","volume":"164","author":"Jeong","year":"2012","journal-title":"Am Heart J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document.","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1055\/s-0038-1626697","article-title":"Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study.","volume":"118","author":"Kang","year":"2018","journal-title":"Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1160\/TH09-07-0491","article-title":"Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies.","volume":"103","author":"Becker","year":"2010","journal-title":"Thromb Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study.","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial.","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/ehjcvp\/pvy018","article-title":"Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry.","volume":"4","author":"Zeymer","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3349\/ymj.2022.63.5.413","article-title":"Platelet function and genotype after DES implantation in East Asian patients: rationale and characteristics of the PTRG-DES Consortium.","volume":"63","author":"Her","year":"2022","journal-title":"Yonsei Med J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ahj.2019.10.001","article-title":"Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: insights from the BleeMACS and RENAMI registries.","volume":"220","author":"D\u2019Ascenzo","year":"2020","journal-title":"Am Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1053867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:37:22Z","timestamp":1670823442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1053867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2022.1053867"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1053867","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"1053867"}}